🧪Research Finds Therapeutic mRNA Protocol Creates Both Toxic Effects and Ineffective Dosage on Diverse Population
Is this really the right time to start vaccinating children in the under 5 crowd?
In mid-August 2021, some New Jersey municipalities announced that third doses of the COVID-19 vaccine were being made available for immunocompromised individuals. Shortly thereafter, on August 18, 2021 the White House held a press briefing indicating that all Americans age 18 and over would become eligible for a booster dose beginning September 20, 2021. Specific guidelines for the timing of administering the booster after primary vaccination has changed over time, however, in hindsight it seems unclear if these boosters created toxicity in some patients, increased protection in some, or offered no significant clinical benefit in others.
Considering the overwhelming reality of COVID-19 ‘breakthrough cases’ that have become all too common among vaccinated individuals and the countless reports of life-altering side effects and even death that have been associated with both the mRNA COVID-19 vaccines designed by Pfizer/BioNTech and Moderna and the viral vector vaccine from Johnson & Johnson approved for use on an emergency basis in the US, many are asking what real benefits - and impacts on human health - this vaccination program will deliver in the near and long term.
The research collaboration quoted below between Children's Hospital of Philadelphia (CHOP) and Novartis Institutes for BioMedical Research is especially interesting within the context of what is being learned about the efficiency and effectiveness of mRNA and viral vector COVID-19 vaccines currently being administered (experimental) under Emergency Use Authorization (EUA) from the FDA. In this study, researchers were seeking to solve problems that arose after the administration of gene therapy in patients. As with the COVID-19 vaccines, maintaining the proper level of expression of the protein production targeted by the therapy is ostensibly a primary factor in what determines the success of the treatment or potential for deleterious effects.
"Once gene therapy has been successfully delivered into the tissue, it is difficult to regulate the levels of expression. Too much expression may have toxic effects on the patient, and too little expression may mean that the patient does not receive the intended benefits of the therapy."
"...CHOP researchers developed a delivery system called the Xon system, which can finely control protein translation by using a “dimmer switch” to adjust the levels of expression up or down as needed."
In mid-February 2022 a decision will be made by an FDA advisory panel about whether to recommend approval of an EUA for a two shot series of the Pfizer/BioNTech Covid-19 vaccine to be administered in the population of American children aged 6 months - 4 years. Widespread and credible statements have been made by the Biden administration’s chief Covid expert intimating that two doses of the product are generally not effective at achieving the desired immune response and a booster shot will be needed to reach an appropriate level of clinical efficacy.
It seems preposterous to ask parents of small children to accept a vaccine approved and offered under these conditions, however that seems to be exactly what’s happening. While many want to trust the advice of their physicians and other healthcare providers, the messaging coming from the top level of this government organized vaccination program seem to be undermining it.
When this type of disparity is observed in any context it’s important to stop and ask some tough questions about motivations, beneficiaries, and potential drawbacks or harm in proceeding. As evidenced by the CHOP quote about gene therapy research quoted above, there can be unknowns and detrimental outcomes even in highly-effective life-saving therapeutic interventions that work in similar ways to the Covid-19 vaccine. Parents of healthy children have a duty to do everything they can to keep them that way. Their future is counting on it.